ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
2023ÄêÓ¦ÓÃÒ©ÎïÆÊÎö×êÑлᣨApplied Pharmaceutical Analysis, APA 2023£©½«ÓÚ9ÔÂ26ÈÕÖÁ28ÈÕÔÚ²¨Ê¿¶Ù¡¤Ä¬¿ËÑо¿ÊµÑéÊÒ¾ÙÐС£
Ó¦ÓÃÒ©ÎïÆÊÎö (APA) Óɲ¨Ê¿¶Ùлᣨ501(c)3 ·ÇÓªÀû×éÖ¯£©ÓÚ 2004 Ä꽨É裬ÊÇÒ»¸öÒÔÐÐÒµÎªÖØµã¡¢»¥¶¯ÐÔ¼«Ç¿µÄÂÛ̳£¬ÌÖÂÛÒ©Îï·¢Ã÷¡¢ÉúÎïת»¯ºÍ¹æ·¶ÉúÎïÆÊÎö¡£Ã¿Äê9ÔÂÓɲî±ðµÄ¿ÆÑ§´ø¶¯ÈË×éÖ¯¿ªÕ¹¾Û»á£¬Î§ÈƵ±ËÞÊÀÎïÆÊÎöºÍÒ©ÎïÑз¢ÖÐÉúÎïת»¯µÄÇ°ÑØÊÖÒÕºÍÓ¦ÓÃÏ£Íû½á¹¹»°Ì⣬ÏòËùÓиÐÐËȤµÄ¿ÆÑ§¼Ò¿ª·Å¡£
APA 2023½«Î§ÈÆÒÔÏÂÆ«ÏòÕö¿ª£ºÉúÎïÆÊÎö¼°Æäî¿Ïµ¡¢Ì½Ë÷ÉúÎïÆÊÎöÐÂÊÖÒÕ¡¢ADMEµÈ¡£
×ðÁú¿Ê±ÍŶӽ«¼ÓÈë±¾´Î¾Û»á£¬²¢´øÀ´¡°The Boost of ADMET, PK and Bioanalysis for Drug Discovery and Development¡±£¨ADMET¡¢PKºÍÉúÎïÆÊÎö¶ÔÒ©ÎïÑз¢µÄÍÆÐж¯Ó㩾«²Êº£±¨£¬ÏòÌýÖÚ·ÖÏíÖÖÖÖ×îа¸Àý£¬ÆÚ´ýÓëÄú¾ÍÐÂÒ©Ñз¢ÐèÇó½»Á÷Ïàͬ¡£
ÈÕÆÚ | 2023Äê9ÔÂ26-28ÈÕ
ËùÔÚ | Ĭ¿ËÑо¿ÊµÑéÊÒ£¬²¨Ê¿¶Ù£¬ÃÀ¹ú
×ðÁú¿Ê±Õ¹Î» | #1
Ò©´ú¶¯Á¦Ñ§¹á´®ÓÚÐÂÒ©Ñз¢µÄʼÖÕ£¬Ã¿¸ö½×¶Î¶¼Óвî±ðµÄʹÃüºÍÓë֮ƥÅäµÄÑо¿ÄÚÈÝ¡£
¾ÝÔ¤¼Æ£¬½ü50£¥µÄºòѡҩÎïÒòÁÆÐ§²»¼Ñ¶øÊ§°Ü£¬ÒÑÍù40£¥µÄºòѡҩÎïÒò¶¾ÐÔ¶øÊ§°Ü£¬ADMEÑо¿¿É¼«ºéÁ÷ƽӰÏìÁÙ´²×îÖÕÀÖ³ÉÓë·ñ£¬ÔçÆÚÆÀ¹ÀADMEÌØÕ÷¹ØÓÚÓÅ»¯Ò©Îï·¢Ã÷ºÍ¿ª·¢Àú³Ì¾ßÓÐÇÐʵ¼ÛÖµ¡£³ýÁ˹ŰåµÄС·Ö×Ӻʹó·Ö×ÓÒ©ÎïÍ⣬ÏÖÔÚ¶ÔëÄÀàÒ©Îï¡¢¹ÑºËÜÕËáºÍADCÒ©ÎïµÈÐÂģʽµÄͶÈëÒ²´ó·ùÔöÌí£¬ÉúÎïÆÊÎöºÍʵÑ鹤¾ßÐèÒª½øÒ»²½Á¢Ò죬ÒÔÖ§³ÖÆäADMEÌØÕ÷Ñо¿¡£
±¾´Î¾Û»á°²ÅÅÁËÈý³¡Ö÷ÌⶨÏò×êÑУºî¿Ïµ¡¢ÊÖÒÕºÍÓ¦Óá£×ðÁú¿Ê±¾«Ñ¡Á˾ۻáÒé³Ì£¬¹©Äú²Î¿¼¡£
Session I: Assessing the Current Landscape of FDA Regulations
£¨FDA¹æÔòµÄÏÖ×´ÆÀ¹À£©
Session II: Advances in Sampling Strategies: A dialogue with Joleen White & Lori Payne
£¨¶Ô»°×¨¼Ò£ºÈ¡ÑùÕ½ÂÔµÄÏ£Íû£©
Session III: Emerging Modalities & New Technologies
£¨ÐÂÐËģʽÓëÐÂÊÖÒÕ
Session IV: Immunogenicity Applications for Various Drug Modalities
£¨²î±ðÁÆ·¨ÏÂÃâÒßÔÐÔÓ¦Óã©
Session V: Rapid Fire Poster Presentations
£¨º£±¨Õ¹Ê¾£©
Session I: Leveraging Biomarkers & Integrating Multi-Omics for Biomarker Discovery
£¨Ê¹ÓÃÉúÎï±ê¼ÇÎïºÍÕûºÏ¶àÖ¸±ê·¢Ã÷ÉúÎï±ê¼ÇÎ
Session II: Applications of Precision Medicine in Drug Discovery Research
£¨¾«×¼Ò½Ñ§ÔÚÒ©Îï·¢Ã÷Ñо¿ÖеÄÓ¦Óã©
Session III: Advancing DMPK/Bioanalysis of PROTAC's
£¨ÍƽøPROTACµÄDMPK/ÉúÎïÆÊÎö£©
Session IV: Latest Advances in LC-MS
£¨LC-MS µÄ×îÐÂÏ£Íû£©
Session I: ADME of Select Modalities
£¨ADMEÄ£×ÓÑ¡Ôñ£©
Session II: Why is My Human ADMET Profile Not as Expected?
£¨ÎªÊ²Ã´ADMETÑо¿Ð§¹û²»ÈçÔ¤ÆÚ£¿£©
Session III: Applying Cutting-edge ADME Technologies
£¨ADMEÇ°ÑØÊÖÒÕÓ¦Óã©
Session IV: Exploring Unconventional Biotransformation Pathways
£¨Ì½Ë÷·ÇͨÀýÉúÎïת»¯Í¾¾¶£©
×ðÁú¿Ê±ÔÚÌåÍâADME¡¢ÌåÄÚÒ©´ú¶¯Á¦Ñ§ºÍÉúÎïÆÊÎöЧÀÍÁìÓòΪ¿Í»§ÌṩÆÕ±éµÄ¸ßÖÊÁ¿Ð§ÀÍ£¬Ð§À͹æÄ£´ÓС·Ö×Óµ½´ó·Ö×Ó£¬ÈçÂѰ×ÖʺͿ¹Ìå¡£ÎÒÃÇÌṩЧÀ͵͝ÎïÖÖÀà°üÀ¨·ÇÈËÁ鳤ÀදÎȮ¡¢Ð¡Êó¡¢´óÊó¡¢Íõȡ£